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Abstract
Background: Atherosclerotic peripheral arterial disease (PAD) affects 8–10 million people in the United States and is
associated with a marked impairment in quality of life and an increased risk of cardiovascular events. Noninvasive
assessment of PAD is performed by measuring the ankle-brachial index (ABI). Complex traits, such as ABI, are influenced
by a large array of genetic and environmental factors and their interactions. We attempted to characterize the genetic
architecture of ABI by examining the main and interactive effects of individual single nucleotide polymorphisms (SNPs)
and conventional risk factors.
Methods: We applied linear regression analysis to investigate the association of 435 SNPs in 112 positional and biological
candidate genes with ABI and related physiological and biochemical traits in 1046 non-Hispanic white, hypertensive
participants from the Genetic Epidemiology Network of Arteriopathy (GENOA) study. The main effects of each SNP, as
well as SNP-covariate and SNP-SNP interactions, were assessed to investigate how they contribute to the inter-individual
variation in ABI. Multivariable linear regression models were then used to assess the joint contributions of the top SNP
associations and interactions to ABI after adjustment for covariates. We reduced the chance of false positives by 1)
correcting for multiple testing using the false discovery rate, 2) internal replication, and 3) four-fold cross-validation.
Results: When the results from these three procedures were combined, only two SNP main effects in NOS3, three SNP-
covariate interactions (ADRB2 Gly 16 – lipoprotein(a) and SLC4A5 – diabetes interactions), and 25 SNP-SNP interactions
(involving SNPs from 29 different genes) were significant, replicated, and cross-validated. Combining the top SNPs, risk
factors, and their interactions into a model explained nearly 18% of variation in ABI in the sample. SNPs in six genes
(ADD2, ATP6V1B1, PRKAR2B, SLC17A2, SLC22A3, and TGFB3) were also influencing triglycerides, C-reactive protein,
homocysteine, and lipoprotein(a) levels.
Conclusion: We found that candidate gene SNP main effects, SNP-covariate and SNP-SNP interactions contribute to
the inter-individual variation in ABI, a marker of PAD. Our findings underscore the importance of conducting systematic
investigations that consider context-dependent frameworks for developing a deeper understanding of the
multidimensional genetic and environmental factors that contribute to complex diseases.
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Atherosclerotic peripheral arterial disease (PAD) affects
8–10 million people in the United States [1,2] and is asso-
ciated with a marked impairment in quality of life and an
increased risk of stroke, myocardial infarction, and cardi-
ovascular death [3]. Noninvasive assessment of PAD is
performed by measuring the ankle-brachial index (ABI),
the ratio of systolic blood pressure (SBP) at the ankle to
the SBP in the arm. Normally ABI is ≥ 1.0, but with
increasing narrowing of the lumen of arteries in the lower
extremities, SBP at the ankle falls. Because individuals
with PAD may not have typical symptoms of exertional
leg discomfort, ABI values ≤ 0.95 or ≤ 0.90 have been used
to diagnose the presence of PAD.
Coronary artery disease, cerebrovascular disease, and PAD
are manifestations of the atherosclerotic disease process.
As such, many of the well-established risk factors for
atherosclerosis, such as increasing age, hyperlipidemia,
hypertension, cigarette smoking and diabetes [4], contrib-
ute to these diseases. While these conventional risk factors
have been associated with PAD, they explain < 20% of
inter-individual variation in ABI [5]. The contribution of
other 'novel' biochemical and genetic risk factors is less
well characterized. In particular, little is known regarding
genetic factors influencing inter-individual variation in
ABI.
A recent review of the few association studies conducted
to date suggests that the investigations of a small number
of genes have failed to uncover compelling genetic deter-
minants of PAD and most studies have only focused on
the main effects of one polymorphism per gene [6]. We
have previously reported findings from an association
study that examined the relationships between variations
in the NOS3 gene and ABI [7]. While this investigation
also focused on a single gene, it extended the literature by
employing a tag SNP approach to adequately cover varia-
tion and investigated the potential influence of 14 poly-
morphisms and related haplotypes on inter-individual
ABI variation. Our findings provided evidence that NOS3
variants may have moderate effects on ABI variation,
which is in line with the conventional wisdom that the
effect of a single gene on a complex disease is expected to
be modest and that genetic susceptibility to complex
atherosclerotic disease is likely polygenic [6]. Further-
more, while the single candidate gene approach, largely
employed to date, may offer valuable insights into the eti-
ology of PAD, it fails to consider the interactive and con-
text-dependent nature that defines complex diseases like
PAD.
As a part of the Genetic Epidemiology Network of Arteri-
opathy (GENOA) study, genetic variants in a large collec-
tion of positional and biological candidate genes have
been measured to better understand the contribution of
genes to risk of arteriopathies that are associated with dis-
eases of the heart, brain, kidneys, and peripheral arteries.
Even with an increased understanding of the molecular
genetic and biochemical basis of blood pressure (BP) reg-
ulation, lipoprotein metabolism, inflammation, oxidative
stress, and glucose metabolism, it has been difficult to pre-
dict individual susceptibility to these diseases [8]. Com-
plex traits, such as ABI, are influenced by a large array of
genetic, environmental, behavioral, and social factors and
their interactions [9]. As such, in order to develop a more
complete picture of genetic susceptibility to PAD, it is nec-
essary to move beyond the exclusive investigation of sin-
gle gene effects. In this paper, we begin to characterize the
complex genetic architecture of ABI by examining the
effect of individual SNPs in candidate genes, interactions
between SNPs and conventional risk factors, as well as
interactions between SNPs within and across genes (intra-
genic and intergenic epistasis). In addition, we investi-
gated whether the SNPs affecting ABI also influence 15
physiological and biochemical correlates of the pathways
underlying variation in ABI. These include age, body mass
index (BMI), smoking, SBP and diastolic blood pressure
(DBP), fasting plasma cholesterol, high-density lipopro-
tein (HDL) cholesterol, triglycerides, C-reactive protein
(CRP), homocysteine, lipoprotein (a) (Lp(a)), fibrinogen,
hypertension, and diabetes. This paradigm shift to a more
encompassing attempt to unravel the complex genetic
architecture is an advance over the simplified single gene
approach employed in the past. While difficult to dissect
and interpret, a deeper understanding of interactive effects
and underlying correlation structures will likely offer
additional insights into the etiology of PAD and possible
explanations for PAD susceptibility for certain individuals
within particular contexts.
For this study, we identified 435 SNPs in 112 genes that
have been previously implicated as playing a role in BP
regulation, lipoprotein metabolism, inflammation, oxi-
dative stress, and diabetes. To our knowledge, no other
study has comprehensively investigated how this amount
of variation in numerous candidate genes may influence
PAD risk. A summary of the genes and their correspond-
ing SNPs is provided [see Additional file 1]. Although
association studies are favored over linkage studies for
unraveling the genetic bases of complex disorders, lack of
replication in a majority of such studies has been a major
concern [10]. To reduce false positives we combined three
approaches: adjustment for multiple testing using the
false discovery rate (FDR) [11], internal replication, and
cross-validation [12].Page 2 of 11
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Study Population
Subjects included non-Hispanic white participants in the
Genetic Epidemiology Network of Arteriopathy (GENOA)
study, a community-based study of hypertensive sibships
that aims to identify genes influencing BP [13,14]. The
study was approved by the Institutional Review Board of
Mayo Clinic, Rochester MN. Written informed consent
was obtained from each participant. In the initial phase of
the GENOA study (9/1995 to 6/2001), sibships contain-
ing ≥ 2 individuals with essential hypertension diagnosed
before age 60 years were selected for participation. At the
Rochester, MN field center, 1583 non-Hispanic whites
were enrolled. Participants returned in Phase II of GENOA
for physical examination, and measurement of non-con-
ventional and novel risk factors as well as the ABI.
Through November of 2004, ABI had been measured in
1046 participants.
Clinical Assessments and Covariate Definitions
Height was measured by stadiometer, weight by electronic
balance, and BMI was calculated as weight in kilograms
divided by the square of height in meters. Resting SBP and
DBP were measured by a random zero sphygmomanom-
eter. Blood was drawn by venipuncture after an overnight
fast. Serum total cholesterol and HDL cholesterol were
measured by standard enzymatic methods. Low-density
lipoprotein (LDL) cholesterol levels were calculated using
the Friedewald formula [15]. The diagnosis of hyperten-
sion was established based on BP levels measured at the
study visit (≥ 140/90 mmHg) or a prior diagnosis of
hypertension and current treatment with antihypertensive
medications. Diabetes was considered present if the sub-
ject was being treated with insulin or oral agents or had a
fasting glucose level ≥ 126 mg/dL. Participants were con-
sidered as having "ever smoked" if they had smoked more
than 100 cigarettes during their lifetime. CRP was meas-
ured by a highly sensitive immunoturbidimetric assay
[16]. Fibrinogen was measured by the Clauss (clotting
time based) method [17]. Lp(a) in serum was measured
by an immunoturbidimetric assay using the SPQ™ Test
System (Diasorin, Stillwater MN) as previously described
[18]. Plasma homocysteine was measured by high-pres-
sure liquid chromatography. Inter-assay coefficients of
variance were: CRP, 2.6–2.8%; fibrinogen, 5.8–6.8%;
Lp(a), 8.6–13.5%; homocysteine, 5.7–7.4%.
Ankle-brachial index
ABI was measured in the supine position following a 5-
min rest. Appropriately sized BP cuffs were placed on each
arm and ankle, and a Doppler ultrasonic instrument
(Medisonics, Minneapolis MN) was used to detect each
pulse. The cuff was inflated to 10 mm Hg above SBP and
deflated at 2 mm Hg/s. The first reappearance of the pulse
was taken as the SBP. To calculate ABI, the SBP at each
ankle site (posterior tibial and dorsalis pedis) was divided
by the higher of the 2 brachial pressures. The lowest of the
4 ratios was designated as the ABI. The correlation of the
lowest ABI with the average of the 2 ABIs from the same
leg was 0.98, and inferences were similar using the lowest
ABI or the average ABI.
SNP Selection
Four hundred and thirty five SNPs from 112 genes known
or hypothesized to be involved in BP regulation, lipopro-
tein metabolism, inflammation, oxidative stress, vascular
wall biology, obesity and diabetes were identified from
the genetic association literature and positional candidate
gene studies [19]. These biological pathways and disease
conditions are related to atherosclerosis. As PAD is an
atherosclerotic process, studying variations in these candi-
date genes may yield insights into the genetic architecture
of ABI. SNPs were chosen based on a number of different
criteria including the published literature, non-synony-
mous SNPs with a minor allele frequency (MAF) > 0.02,
and tag SNPs using public databases such as dbSNP [20]
and Seattle SNPs [21].
Our algorithm for SNP selection first identified non-syn-
onymous SNPs with a minor allele frequency (MAF) >
0.02 based on data from the Seattle SNPs database [21].
Second, we identified all SNPs with a MAF > 0.1 and
unique sequence context that could potentially be typed
in any of the three ethnic groups (non-Hispanic white,
African-American, Hispanic) sampled in the GENOA
study [13]. From the latter SNPs, tag SNPs were selected
based on the r2 method described by Carlson et al. [22].
The final list of SNPs to be genotyped was established by
selecting 1 SNP from each bin pair according to the fol-
lowing selection prioritization: (first) a tag SNP in a con-
served region (compared to mouse); (second) a tag SNP
not in a conserved region; (third) a non-tag SNP in a con-
served region; (fourth) neither a tag SNP nor a SNP in a
conserved region. We used this priority system because
several bins had multiple tag SNPs, and some bins had no
identified tag SNPs.
Genotyping
DNA was isolated using the PureGene DNA Isolation Kit
from Gentra Systems (Minneapolis MN). Genotyping,
based on polymerase chain reaction (PCR) amplification
techniques, was conducted at the University of Texas-
Health Sciences Center at Houston using the TaqMan
assay and ABI Prism® Sequence Detection System (Applied
Biosystems, Foster City CA). Primers and probes are avail-
able from the authors upon request. Quality control
measures for genotyping assays included robotic liquid
handling; separate pre- and post-PCR areas; standard pro-
tocols and quality control analyses including 5% dupli-Page 3 of 11
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sample tracking, and data validity checks.
Statistical Analysis
All analyses were carried out using the R statistical lan-
guage [23]. Variables with skewed distributions were log
transformed. Risk factor correlations were estimated using
Pearson's product moment correlation. Allele and geno-
type frequencies were calculated using standard gene
counting methods. Linkage disequilibrium (LD), as meas-
ured by r2 [24], was estimated using an expectation maxi-
mization (EM) algorithm. Hardy-Weinberg Equilibrium
was assessed using a chi-square test or Fisher's exact test if
a genotype class had less than 5 individuals [25]. In all
models, ABI was adjusted for age, sex, BMI, smoking sta-
tus (ever vs. never), diabetes, and hypertension. Adjust-
ment variables were chosen because they have known
associations with PAD [2,26-29] or because they were sta-
tistically significant predictors of ABI in this dataset.
In the first stage of analysis, we tested for associations of
each of the predictors (SNPs and demographic/biochemi-
cal risk factors) with ABI using least-squares linear regres-
sion methods [30]. We also tested for association between
each single SNP and each risk factor to identify potential
confounders. To determine whether interactions among
predictors explained additional variation in ABI, we tested
pairwise interactions among all possible pairs of predic-
tors (i.e. SNP-SNP, SNP-risk factor, and risk factor-risk fac-
tor interactions). Associations involving interactions were
assessed with a partial F test, which compares a full model
that includes both the interaction terms and the main
effects of the variables comprising the interaction terms to
a reduced model that includes only the main effects.
To reduce false positives we used three different
approaches: adjustment for multiple testing using FDR <
0.30 [11], internal replication with two subsets of unre-
lated individuals followed by testing for homogeneity of
genotype-phenotype effects, and, finally, four-fold cross-
validation (repeated 10 times) [31]. To create replication
subsets, we randomly selected 1 hypertensive sib from
each sibship without replacement to create Subset 1 and
then randomly selected another hypertensive sib from
each sibship to create Subset 2. The GENOA cohort con-
tained a small number of singletons (i.e.- no matching
sibs) that were equally divided between the two samples.
A dichotomous "sample" variable was generated, with all
subjects in Subset 1 assigned a value of 0 and all subjects
in Subset 2 assigned a value of 1. If an effect was found to
be significant in both subsets, modeling an interaction
term between the significant SNP and the "sample" varia-
ble was used to assess the homogeneity of the respective
genotype-phenotype effect. This interaction model was
then compared to a reduced model without the "sample"
interaction and significance was assessed with a partial F-
test.
Cross-validation significantly reduces false positive results
by eliminating associations that lack predictive ability in
independent test samples. We performed four-fold cross-
validation by dividing the full sample into four equally
sized groups. Three of the four groups were combined into
a training dataset, and the modeling strategy outlined
above was carried out to estimate model coefficients.
These coefficients were then applied to the fourth group,
the testing dataset, to predict the value of the outcome var-
iable of each individual in the independent test sample.
This process was repeated for each of the 4 testing sets.
Predicted values for all individuals in the test set were then
subtracted from their observed values, yielding the total
residual variability (SSE), . The total varia-
bility in the outcome (SST) – the difference between each
individual's observed value and the mean value for the
outcome – was then calculated, . In order to
estimate the proportion of variation in the outcome pre-
dicted in the independent test samples, the cross-vali-
dated R2 (CV R2) was calculated as follows:
. This cross-validation method provides
a more accurate measure of the predictive ability of the
genetic models and will be negative when the model's pre-
dictive ability is poor. Because random variations in the
sampling of the four mutually exclusive test groups can
potentially impact the estimates of CV R2, this procedure
was repeated 10 times and the CV R2 values were averaged
[31]. Univariate associations were considered cross-vali-
dated if the average percent variation predicted in inde-
pendent test samples was greater than 0.5% and
interactions were considered cross-validated if the differ-
ence in average percent variation predicted in independ-
ent test samples between the full model containing the
interaction term and the reduced model containing only
main effect terms was greater than 0.5%.
To visualize the genetic architecture of ABI, we applied a
novel data visualization scheme, the KGraph, described in
Kelly et al. [32]. The KGraph was developed for the visual-
ization of genetic association results and the underlying
confounding due to SNP-SNP frequency correlations (i.e.
LD), SNP-risk factor associations, and risk factor-risk fac-
tor correlations. It simultaneously displays both signifi-
cant univariate associations and pairwise interactions
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ing correlation structure among the predictor variables
(SNPs and risk factors).
Using a SNP list that was comprised of SNPs that passed
our three filters (FDR, replication, and cross-validation),
multivariable linear regression models combining the top
SNPs, risk factors, and their interactions were then con-
structed and the percent variation in ABI explained by
each model was estimated. Four-fold cross validation was
used to estimate the predictive ability of these models in
test samples not used to estimate the models.
Results
The descriptive statistics for the full sample of non-His-
panic whites and the two subsets used to examine replica-
tion are presented in Table 1. The mean age was 59 years.
The mean BMI was 31 kg/m2. The average ABI was 1.11.
Fifteen percent of the participants had type II diabetes and
51% had a history of smoking.
In Table 2, we present a summary of the results from test-
ing for SNP main effects, SNP-covariate, and SNP-SNP
interactions and the number of associations that
remained significant after adjustment for multiple testing
(FDR < 0.3), testing for replication, and cross-validation.
For example, 435 SNPs were evaluated for their associa-
tion with adjusted ABI and 20 had FDR < 0.3, 3 internally
replicated, and 5 cross-validated. Only two SNPs (located
in the NOS3 gene, rs891512 and rs1808593) passed all
three filters. In contrast, there were 6,926 tests of SNP-risk
factor interactions and 20 had a FDR < 0.3, 72 internally
replicated, but only 52 cross-validated. Only three SNP-
risk factor interactions passed all three criteria – specifi-
cally, ADRB2_rs1042713 interacting with Lp(a) and
SLC4A5 polymorphisms interacting with diabetes (Table
3). There were 91,113 tests of SNP-SNP interactions and
we found 270 had a FDR < 0.3, 973 internally replicated,
and 404 cross-validated. Only 25 SNP-SNP interactions
passed all three criteria and are listed in Table 3.
Figure 1 is a visual representation of the complex genetic
and demographic/biochemical risk factor associations
underlying variation in ABI. Using both color and spatial
relationships, the KGraph presents both associations with
ABI and the correlation structure of the predictors that
underlie those associations. Only SNPs that passed all
three filters are displayed, though all SNP-ABI, SNP-SNP
(i.e. LD), and SNP-risk factor associations are represented
to more fully understand the complex correlation struc-
ture underlying ABI predictors. Region 1, shown in green,
displays the association between the SNPs and biochemi-
Table 1: Descriptive Statistics for Study Participants
Full Sample (N = 1046) Subset 1 (N = 330) Subset 2 (N = 329) Univariate association with ABI in full 
sample (N = 1046)
Mean (± SD) Mean (± SD) Mean (± SD) β estimate
ABI 1.1 (0.1) 1.1 (0.2) 1.1 (0.1)
Age, years 59.1 (10.1) 60.8 (9.1) 61.3 (9.0) -3.6E-03***
BMI, kg/m2 30.9 (6.2) 31.1 (6.1) 31.9 (6.3) 2.9E-03***
Waist Hip Ratio, cm 0.91 (.11) 0.92 (0.1) 0.92 (0.1) 1.1E01*
SBP, mm Hg 131.1 (16.6) 135.1 (17.4) 135.0 (16.3) -1.6E-03***
DBP, mm Hg 74.0 (9.0) 74.9 (9.7) 74.5 (9.2) 1.8E-03***
Pulse pressure, mm Hg 57.2 (15.3) 60.2 (15.8) 60.5 (16.1) -2.5E-03***
Total cholesterol, mg/dL 196.7 (34.9) 193.0 (32.8) 195.2 (33.4) -2.5E-05
HDL cholesterol, mg/dL 51.4 (14.9) 49.8 (14.3) 50.8 (14.0) -8.1E-04**
LDL cholesterol, mg/dL 113.8 (31.8) 125.1 (36.5) 126.1 (36.6) 2.8E-04
Triglycerides, mg/dL 159.9 (96.1) 163.8 (97.7) 163.0 (90.0) -7.4E-05
C-reactive protein, mg/L 0.45 (0.7) 0.50 (0.9) 0.45 (0.5) -7.2E-03
Fibrinogen, mg/dL 318.3 (77.0) 321.0 (73.6) 324.7 (78.3) -1.7E-04**
Homocysteine, umol/L 9.9 (2.7) 10.2 (2.8) 10.1 (2.8) -4.9E-03**
Lp(a), mg/dL 40.1 (38.7) 40.5 (36.5) 40.4 (40.5) -4.6E-04**
Female, n (%) 580 (55%) 170 (52%) 183 (56%) -5.4E-02***
Ever smoker, n (%) 528 (51%) 174 (53%) 161 (49%) -1.4E-02
Diabetes, n (%) 154 (15%) 48(15%) 71(22%) -2.4E-02
Hypertensive, n (%) 773 (74%) 330 (100%) 329 (100%) -3.7E-02***
*p < 0.05; ** p < 0.01; *** p < 0.001
ABI, ankle-brachial index; BMI, body mass index; SBP, systolic blood pressure; DBP, diastolic blood pressure; HDL, high density lipoprotein; LDL, 
low density lipoprotein; Lp(a), lipoproteinPage 5 of 11
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ing and information about underlying metabolic
pathways. In this region, the cross-validated SNP associa-
tions with log triglyceride (TGFB3 and SLC22A3), log CRP
(ADD2), fibrinogen (ATP6B1), homocysteine (SLC17A2
and PKRAR2B), and Lp(a) (SLC22A3) are indicated.
Region 2, shown in grey, illustrates the correlations
between the risk factors. The majority of the risk factors
Table 2: Quantitative summary of genetic associations with ABI that replicated, cross-validated, and passed FDR criterion
SNP Main Effects SNP-Covariate Interactions SNP-SNP Interactions
Number of tests 435 6926 91113
P < 0.10 on full sample 77 815 10308
FDR (< 0.30) on full sample 20 20 270
Cross Validation (on full sample) 5 52 404
Replication (P < 0.10 in both groups) 3 72 973
FDR and Cross-validation 5 14 79
FDR and Replication 2 4 36
Replication and Cross-validation 2 7 52
FDR and Cross-Validation and Replication 2 3 25
FDR, False Discovery Rate
Genetic architecture of the ankle-brachial index in non-Hispanic WhitesFigure 1
Genetic architecture of the ankle-brachial index in non-Hispanic Whites.Page 6 of 11
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Table 3: Genetic effects that replicated, cross-validated, and passed FDR criterion
Main Effects (2) SNP Subset 1 p-value Subset 2 p-value Full Sample p-
value
R2 CV R2
NOS3_rs891512 0.0003 0.0458 0.0005 0.0151 0.0096
NOS3_rs1808593 0.0006 0.0333 0.0001 0.0178 0.0105
SNP-Covariate 
Interactions (3)
SNP Covariate R2 CV R2
ADRB2_rs1042713 Lp(a) 0.0847 0.0407 0.0006 0.0176 0.0089
SLC4A5_rs828853 DIABETES 0.0564 0.0462 0.0004 0.0143 0.0095
SLC4A5_rs1299142
4
DIABETES 0.0350 0.0278 0.0005 0.0106 0.0085
SNP-SNP 
Interactions (25)
SNP1 SNP2 R2 CV R2
TTRAP_rs1129644 HLA-DOA_rs2581 0.0535 0.0608 0.0001 0.0198 0.0116
ADD2_rs2110981 TGFB3_rs2268622 0.0355 0.0134 0.0004 0.0171 0.0115
ADD2_rs2110981 TGFB3_rs2284791 0.0439 0.0049 0.0001 0.0200 0.0156
ADD2_rs2270042 AGT_rs5049 0.0085 0.0765 0.0003 0.0171 0.0127
ADRB2_rs1042713 PRL_rs1205960 0.0066 0.0885 0.0003 0.0175 0.0119
ATP6V1B1_rs11681
642
IL1B_rs3917356 0.0223 0.0105 0.0002 0.0195 0.0130
ATP6V1B1_rs10247
64
ACCN4_rs3755065 0.0395 0.0005 0.0002 0.0189 0.0152
ATP6V1B1_rs22394
84
ACCN4_rs3755065 0.0550 0.0005 0.0005 0.0161 0.0121
ATP6V1B1_rs22394
87
ACCN4_rs3755065 0.0238 0.0013 0.0004 0.0175 0.0123
AUP1_rs10779958 SLC2A2_rs5400 0.0041 0.0868 0.0003 0.0155 0.0149
SCN7A_rs1406275 TGFB3_rs3917195 0.0283 0.0004 0.0001 0.0180 0.0137
FGB_rs4220 KCNE4_rs3795884 8.98E-05 0.0584 3.45E-05 0.0208 0.0163
GPC6_rs1924115 IL6_rs2069827 0.0203 0.0338 0.0007 0.0145 0.0124
ICAM1_rs5030352 SLC19A3_rs121857
21
0.0869 0.0028 0.0001 0.0172 0.0073
MMP3_rs683878 VCAM1_rs1041163 0.0644 0.0407 0.0003 0.0172 0.0085
MMP9_rs20544 SLC12A3_rs230448
3
0.0157 0.0876 0.0002 0.0180 0.0132
SLC4A5_rs702462 TGFB3_rs3917187 0.0734 0.0010 0.0004 0.0176 0.0088
SLC4A5_rs702462 TGFB3_rs3917201 0.0456 0.0010 7.65E-05 0.0207 0.0147
SLC4A5_rs702462 TGFB3_rs3917210 0.0329 0.0009 4.62E-05 0.0222 0.0156
SLC4A5_rs702462 TGFB3_rs3917211 0.0358 0.0015 5.91E-05 0.0212 0.0097
PRKAR2B_rs257376 SLC17A2_rs154027
3
0.0075 0.0036 0.0005 0.0174 0.0134
PRKAR2B_rs257376 SLC17A2_rs207129
9
0.0161 0.0020 0.0002 0.0182 0.0103
PLIN_rs1052700 TGFB3_rs3917195 0.0126 0.0015 0.0006 0.0146 0.0054
SELE_rs5368 SLC22A3_rs668871 0.0004 0.0954 0.0005 0.0167 0.0127
SELE_rs5356 SLC22A3_rs668871 0.0009 0.0932 0.0006 0.0157 0.0124
All associations adjusted for age, gender, body mass index, smoking, diabetes, and hypertension.
ACCN4 amiloride-sensitive cation channel 4, pituitary; ADD2 adducin 2 (beta); ADRB2 *b2-adrenergic receptor; AGT angiotensinogen (serine (or 
cysteine) proteinase inhibitor, clade A (alpha-1 antiproteinase, antitrypsin), member 8); ATP6V1B1 ATPase, H+ transporting, lysosomal 56/58 kDa, 
V1 subunit B, isoform 1 (Renal tubular acidosis with deafness); AUP1 ancient ubiquitous protein 1; FGB fibrinogen, B beta polypeptide; GPC6 glypican 
6; HLA-DOA human leukocyte antigen; ICAM1 intercellular adhesion molecule 1 (CD54), human rhinovirus receptor; ILB1 interleukin 1, beta; IL6 
interleukin 6 (interferon, beta 2); KCNE4 potassium voltage-gated channel, Isk-related family, member 4; MMP3 matrix metalloproteinase 3 
(stromelysin 1, progelatinase); MMP9 matrix metalloproteinase 9 (gelatinase B, 92 kDa gelatinase, 92 kDa type IV collagenase); NOS3 nitric oxide 
synthase 3 (endothelial cell); PLIN perilipin; PRKAR2B protein kinase, cAMP-dependent, regulatory, type II, beta; PRL prolactin; SCN7A sodium 
channel, voltage-gated, type VII, alpha; SELE selectin E (endothelial adhesion molecule 1); SLC2A2 solute carrier family 2 (facilitated glucose 
transporter), member 2; SLC2A5 solute carrier family 4, sodium bicarbonate cotransporter, member 5; SLC12A3 solute carrier family 12 (sodium/
chloride transporters), member 3; SLC17A2 solute carrier family 17 (sodium phosphate), member 2; SLC19A3 solute carrier family 19, member 3; 
SLC22A3 solute carrier family 22 (extraneuronal monoamine transporter), member 3; TGFB3 transforming growth factor, beta 3; TTRAP TRAF and 
TNF receptor associated protein; VCAM1 vascular cell adhesion molecule 1.
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els not being highly correlated with other risk factors. The
observed LD, shown in red in Region 3, occurs between
SNPs that are within the same gene, with SNPs in the
TGFB3, SELE, NOS3, and SLC4A5 genes being highly cor-
related.
The remaining regions are colored blue, indicating that
they represent associations with ABI. Region 4, which dis-
plays the univariate association between risk factors and
ABI shows that age, BMI, gender, hypertension, SBP, DBP,
pulse pressure, and Lp(a) each have statistically significant
and cross-validated associations with ABI. Region 5,
which illustrates univariate associations between the SNPs
and ABI, reveals that only two SNPs in NOS3 (which are
in LD) have significant, replicated and cross-validated
associations. Region 6 displays the risk factor-risk factor
interactions significantly associated with ABI. Cross-vali-
dated interactions were observed between diabetes status
and Lp(a). Region 7 displays the interactions between the
SNPs and risk factors that were associated with ABI. Over-
all, we detected 10 statistically significant interactions
between a variety of risk factors and SNPs that replicated
and cross-validated. Upon controlling for multiple testing
with FDR, only 3 risk factor-SNP interactions met our cri-
teria. Namely, two SNPs within the SLC4A5 gene
(rs828853 and rs12991424) interacted with diabetes, and
one SNP within the ADRB2 gene (rs1042713) interacted
with Lp(a). Region 8 displays the epistatic (SNP-SNP)
interactions significantly associated with ABI. We detected
32 replicated and cross-validated, statistically significant
pairwise interactions between SNPs. This number was
reduced to 25 interactions after controlling for multiple
testing with FDR. Approximately half of these interactions
involved variants in the solute-carrier genes (7 interac-
tions) and TGFB3 gene (5 interactions).
To begin to assess the combined predictive ability of the
top SNPs, risk factors, and their interactions, we used mul-
tivariable modeling techniques and investigated the per-
cent variation in ABI explained in the full sample and in
the independent test samples used in the cross validation
(i.e. a more accurate estimate of the predictive ability of
these variations for other yet to be sampled individuals in
this population of inference) (see Table 4). We found that
the two single SNPs that met our criteria explained 0.65
percent of variation (adjusted R2) in ABI alone (not
adjusting for risk factors) and the top four SNP-SNP inter-
actions explained an additional 4.5% of variation in ABI.
The covariates explained 12.5% of the variability in ABI
alone while the top SNP-covariate interactions explained
an additional 2.25% (adjusted R2 = 15.04). After account-
ing for risk factors and their interactions with SNPs, the
top SNP-SNP interactions explained an additional 1.75%.
Combining the top SNPs, risk factors, and their interac-
tions into a model explained 17.85% of variation in ABI
in the sample. To assess the predictive ability of these
models in new individuals from the same population we
used cross-validation methods and estimated the CV R2
(see Methods). The predictive ability of the genetic varia-
tions appears to be modest, at best, compared to the cov-
ariates.
Discussion
Multiple studies have investigated the association of pol-
ymorphisms in candidate genes with essential hyperten-
sion and coronary heart disease, but relatively few studies
have explored the relationship between specific candidate
gene polymorphisms and ABI, a marker of PAD. Our
motivating hypothesis was that genetic polymorphisms
implicated in risk factors for hypertension and CHD may
influence PAD risk by means of common pathophysiolog-
ical pathways. Therefore, in order to understand the
genetic architecture of a complex multifactorial trait such
as ABI, larger scale investigations of the polygenic network
of genes and their impact on underlying physiological
and biochemical correlates need to be examined simulta-
neously [33]. Out of 112 biological and positional candi-
date genes, SNPs in 30 different genes were related to
inter-individual variation in ABI, a non-invasive measure
of PAD, in our study. Six of these genes were also associ-
ated with underlying physiological correlates.
Even after adjustment for conventional risk factors and
stringent type I error reduction techniques, two of the
NOS3 SNPs shared significant associations with ABI, sug-
Table 4: Multivariable analysis to assess combined predictive ability of the best SNPs, risk factors, and interactions
Model Adj R2 CV R2
Single Replicated and CVD SNPs 0.0065 0.0009
Single SNPs + Top 4 SNP*SNP Interactions 0.0515 0.0066
CVD Covariates 0.1252 0.1040
CVD Covariates + Single SNPs 0.1397 0.1178
CVD Covariates + Single SNPs + 3 SNP*Covariate Interactions 0.1504 0.1118
CVD Covariates + Single SNPs + Top 4 SNP*SNP Interactions 0.1652 0.0877
CVD Covariates + Single SNPs + 3 SNP*Covariate Interactions + Top 4 SNP*SNP Interactions 0.1785 0.0963
CVD, cross-validated; SNPs, Single Nucleotide PolymorphismsPage 8 of 11
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inter-individual variation in ABI. We did genotype the
well-known NOS3 non-synonymous SNP Asp298Glu
(rs1799983), which has been postulated to alter function
of NOS3 [34], but did not find the SNP to be associated
with ABI. These findings are consistent with our previous
report of an association between polymorphisms in NOS3
and inter-individual variation in ABI [7].
Diabetes is one of the main risk factors for PAD. Several
studies have identified genetic variants that increase risk
for PAD among type 2 diabetics [35-37]. As such, it is
plausible that genetic susceptibility to PAD is modified by
diabetes status. In line with this, 2 of the 3 SNP-covariate
interactions that passed our stringent criteria involved dia-
betes as the environmental covariate. While the preva-
lence of diabetes was low in our sample, our results
provide preliminary evidence for a gene-environment
interaction, even after adjustment for conventional risk
factors. This finding underscores the importance of con-
sidering the particular contexts that may potentially mod-
ify genetic susceptibility to complex disease.
An interesting finding from our study is that the majority
of significant genetic effects were in the form of epistatic
interactions. This finding provides further evidence that
the genetic susceptibility to complex atherosclerotic dis-
eases is not attributable to the modest effects of a single
gene and is likely a result of a combination of alleles in
multiple genes [6]. Animal and plant studies have also
recently shown an abundance of epistatic interactions,
more than had previously been expected [38].
In the clinical setting, ABI is used as a dichotomous varia-
ble, with cut off values of ≤ 0.90 or ≤ 0.95 employed to
confirm the presence of PAD. We did not analyze ABI as a
dichotomous variable as this entailed a substantial loss of
statistical power, particularly since the prevalence of an
abnormal ABI (defined as ≤ 0.90) was low (6.8%) in our
study sample. Despite this, our analyses with ABI as a con-
tinuous outcome were warranted as recent studies suggest
that, even in the range of 1.0–1.3, lower ABI may be
related to PAD risk factors [39]. Furthermore, just as
genetic variation influencing BP variation in normoten-
sives has been related to an increased risk of hypertension
[40], we expected that genetic variation associated with
ABI levels might be related to an increased risk of PAD.
An interesting result from this study is the relatively low
level of agreement between results filtered through differ-
ent methods of reducing false positives – namely, adjust-
ment for multiple testing using FDR < 0.30, internal
replication, and four-fold cross-validation. One of the
shortcomings of genetic association studies is that they
have often failed to replicate and Manly [10] suggests that
internal validation, common to good experimental prac-
tices, is one way to avoid the publication of false positives.
In our study, we used cross-validation methods to signifi-
cantly reduce the chance of false positives. Cross-valida-
tion methods were developed in the late 1970's as a way
to incorporate a measure of predictive accuracy (and cor-
respondingly, a measure of prediction error) for an esti-
mated model based on its performance predicting the
outcome for independent test cases [12]. During the last
decade, cross-validation methods have been used widely
for everything from robust variable selection in gene
expression array studies [41] to reducing false positives in
gene-gene interaction studies [42,43] to evaluating the
predictive accuracy of molecular or genetic classifiers of
disease before clinical implementation [44]. Cross-valida-
tion has become a standard in the field of metabolomic
[45], proteomic [46,47], and transcriptomic [48] studies
because of its ease of execution and its emphasis on pre-
diction in independent test cases as a method of discrim-
inating between true associations and false associations.
We should note that although it appeared in this study
that FDR was more conservative than cross-validation or
internal replication, this is not always the case. We have
conducted similar analyses in other studies (results not
shown) and have found cross-validation to be more con-
servative than the FDR, leading us to the general conclu-
sion that multiple methods should be employed
simultaneously to reduce type I errors for genetic associa-
tion studies.
Concerns have been raised that population stratification
may lead to spurious results in genetic association studies
[44]. To address this potential impact, we assessed the
presence of population substructure using STRUCTURE
[49] and found no evidence of subpopulation clusters in
our sample. Wacholder et al. have pointed out that "pop-
ulation stratification does not occur in an ethnically
homogeneous population" [50] and the bias that may
arise in a population-based study of non-Hispanic Cauca-
sians, as a result of ignoring ethnicity, is likely to be very
small [51].
Some limitations of the present study need to be consid-
ered. Our approach was based on the premise that suscep-
tibility alleles for common diseases (and related
subclinical disease measures such as ABI) are not under
strong negative selection, and common variants contrib-
ute to common disease traits (i.e. the 'common disease –
common variant' hypothesis) [52]. However, the allelic
spectrum for genes associated with complex quantitative
traits such as ABI is not fully delineated, and it is possible
that multiple rare polymorphisms in the biological and
positional candidate genes that we studied influence ABI.
Due to a lack of power, identifying association with ABIPage 9 of 11
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approaches employed in this study. Our inferences may
not be generalizable to individuals who are younger, nor-
motensive, or of other ethnicities. Although a priori
power calculations indicated that we were adequately
powered to detect relatively small SNP effects, insufficient
sample sizes (full sample and re-sampled subsets) or ran-
dom measurement error may have limited our power to
detect genotype-phenotype associations. Despite some
limitations, our approach illustrates the use of SNPs in
candidate genes to construct a more complete picture of
the genetic architecture of complex traits such as ABI.
Conclusion
The genetic architecture of complex multifactorial traits
includes common genetic variants with small effects as
well as gene-gene and gene-environment interactions. We
report that candidate gene SNP main effects, SNP-covari-
ate and SNP-SNP interactions contribute to the inter-indi-
vidual variation in ABI, a marker of PAD. Our findings
underscore the importance of conducting systematic
investigations that consider a context-dependent frame-
work for developing a deeper understanding of the multi-
dimensional genetic and environmental factors that
contribute to complex diseases.
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